Titre:
  • Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.
Auteur:Olivotto, Iacopo; Oreziak, Artur; Barriales-Villa, Roberto; Abraham, Theodore P; Masri, Ahmad; Garcia-Pavia, Pablo; Saberi, Sara; Lakdawala, Neal NK; Wheeler, Matthew MT; Owens, Anjali; Kubanek, Milos; Wojakowski, Wojciech; Jensen, Morten K; Gimeno-Blanes, Juan; Afshar, Kia; Myers, Jonathan; Hegde, Sheila SM; Solomon, Scott D; Sehnert, Amy AJ; Zhang, David; Li, Wanying; Bhattacharya, Mondira; Edelberg, Jay JM; Waldman, Cynthia Burstein; Lester, Steven J; Wang, Andrew; Ho, Carolyn Y; Jacoby, Daniel; Bondue, Antoine
Informations sur la publication:Lancet, 396, 10253, page (759-769)
Statut de publication:Publié, 2020-09
Sujet CREF:Cardiologie et circulation
Médecine interne
MeSH keywords:Adrenergic beta-Antagonists -- therapeutic use
Aged
Benzylamines -- adverse effects -- therapeutic use
Calcium Channel Blockers -- therapeutic use
Cardiac Myosins -- antagonists & inhibitors
Cardiomyopathy, Hypertrophic -- drug therapy -- physiopathology
Cardiovascular Agents -- therapeutic use
Double-Blind Method
Exercise Tolerance -- physiology
Female
Hemodynamics -- physiology
Humans
Male
Middle Aged
Oxygen Consumption -- physiology
Patient Outcome Assessment
Uracil -- adverse effects -- analogs & derivatives -- therapeutic use
Langue:Anglais
Identificateurs:urn:issn:0140-6736
info:doi/10.1016/S0140-6736(20)31792-X
info:pii/S0140-6736(20)31792-X
info:pmid/32871100